Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
89 hedge funds and large institutions have $426M invested in Endocyte, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 27 increasing their positions, 14 reducing their positions, and 15 closing their positions.
395% more capital invested
Capital invested by funds: $86.1M → $426M (+$340M)
120% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 15
93% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 14
54% more call options, than puts
Call options by funds: $4.91M | Put options by funds: $3.19M
25% more funds holding
Funds holding: 71 → 89 (+18)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$31.4M |
| 2 |
VMI
VHCP Management II
New York
|
+$23.7M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.2M |
| 4 |
DM
Deerfield Management
New York
|
+$14.5M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$12.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.37M |
| 2 |
D.E. Shaw & Co
New York
|
-$2.55M |
| 3 |
Millennium Management
New York
|
-$745K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$662K |
| 5 |
Renaissance Technologies
New York
|
-$547K |
ECYT Hedge Fund Activity: Q1 2018 in Review
89 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q1 2018, worth a combined $426M — up 395% from $86.1M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ECYT positions and 15 closed out — a net gain of 18 holders — while 27 added to existing stakes and 14 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $31.4M. The largest seller was Fidelity Investments, cutting an estimated $9.37M.
- 89 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q1 2018, up from 71 in Q4 2017.
- Funds reported $426M of Endocyte, Inc. Common Stock stock for Q1 2018, up 395% quarter-over-quarter.
- 33 funds opened new Endocyte, Inc. Common Stock positions in Q1 2018 and 15 closed out, a net change of +18 holders.
- The largest Endocyte, Inc. Common Stock buyer in Q1 2018 was Avoro Capital Advisors, an estimated $31.4M added.
- The largest Endocyte, Inc. Common Stock seller in Q1 2018 was Fidelity Investments, an estimated $9.37M sold.
Based on aggregated 13F filings for Q1 2018.